Melanin-Concentrating Hormone

What is Melanin-Concentrating Hormone?

Melanin-concentrating hormone (MCH) is a small cyclic neuropeptide first isolated and characterized in 1983 by Hiroshi Kawauchi, I. Kawazoe, M. Tsubokawa, M. Kishida, and B.I. Baker, who purified it from chum salmon (Oncorhynchus keta) pituitary and named it for its ability to concentrate melanin granules within fish melanophores — producing the pale-skin response that is the inverse of the alpha-MSH-driven skin-darkening response. The mammalian homolog is a 19-amino-acid peptide cleaved from the prepro-MCH precursor encoded by the PMCH gene, with a characteristic intramolecular disulfide bond between Cys7 and Cys16 that closes the molecule into a cyclic structure. Despite its fish-pigmentation namesake, the dominant role of MCH in mammals is in the central nervous system rather than the skin: MCH is produced almost exclusively by neurons in the lateral hypothalamic area and zona incerta, with widespread axonal projections throughout the brain. Mammalian MCH signals through two G-protein-coupled receptors — MCH-R1 (MCHR1, also called SLC-1 or GPR24), which is the dominant and physiologically relevant receptor in all mammals, and MCH-R2 (MCHR2), which is functional in primates, carnivores (dogs, ferrets), and several other lineages but exists only as a non-functional pseudogene in rodents. Central administration of MCH in rodents robustly stimulates food intake, established by Qu, Ludwig, Lowell, Maratos-Flier, and Flier in their 1996 Nature paper, and MCH-knockout mice are lean, hypophagic, and resistant to diet-induced obesity (Shimada, Tritos, Lowell, Flier, Maratos-Flier, Nature 1998). MCH-R1 antagonists have been an active obesity drug-discovery target for roughly 25 years across multiple major pharmaceutical companies (Amgen, Pfizer, Synaptic, GSK, Neurocrine, Procter & Gamble, and others), with SNAP-7941 (Borowsky et al., Nature Medicine 2002) emerging as a key tool compound. No MCH-R1 antagonist has reached approval — multiple candidates have been discontinued in development, often for cardiovascular (hERG-channel-related) or CNS tolerability reasons.

What Melanin-Concentrating Hormone Is Investigated For

MCH is an endogenous-biology and drug-target topic, not a peptide consumers take. Its central role as an orexigenic signal in the lateral hypothalamus is among the most thoroughly characterized in modern neuroendocrinology — pharmacological and genetic loss-of-function (MCH-R1 antagonists, MCH knockout, MCH-R1 knockout) all converge on a lean, hypophagic, diet-induced-obesity-resistant phenotype, and pharmacological gain-of-function (intracerebroventricular MCH) drives robust feeding. That mechanistic clarity drove an enormous pharmaceutical effort: from the late 1990s through the mid-2010s, essentially every major obesity drug-discovery program included an MCH-R1 antagonist series. Despite hundreds of compounds, multiple clinical candidates, and preclinical efficacy that often matched or exceeded incumbents, no MCH-R1 antagonist has reached approval. The recurring failure modes have been cardiovascular (hERG-channel inhibition with QT-interval risk), CNS tolerability (anxiety, mood, sleep effects), and pharmacokinetic challenges in achieving brain exposure with adequate selectivity. The 2007 Mendez-Andino and Wos Drug Discovery Today review captures the field's frustration in its title: 'MCH-R1 antagonists: what is keeping most research programs away from the clinic?' MCH biology beyond feeding has continued to expand — REM sleep regulation, reward and motivation, anxiety and mood, and developmental and reproductive roles — but the obesity drug story, despite excellent target validation, has not yet produced an approved medicine.

History & Discovery

MCH was discovered in 1983 by Hiroshi Kawauchi, I. Kawazoe, M. Tsubokawa, M. Kishida, and B.I. Baker, working at Kitasato University in Japan and the University of Bath in the United Kingdom. The team purified a 17-amino-acid cyclic peptide from chum salmon (Oncorhynchus keta) pituitary that produced rapid and reversible aggregation of melanin granules within fish melanophores — pale skin. The September 1983 Nature paper, 'Characterization of melanin-concentrating hormone in chum salmon pituitaries,' established the structure, source, and namesake activity. The functional context of the discovery — fish skin pigmentation — gave the peptide its name and positioned it as the functional inverse of alpha-MSH. The mammalian PMCH gene was cloned in 1989-1990 by Jean-Louis Nahon and colleagues, with the human MCH mRNA structure reported in 1990 (Mol Endocrinol). The mammalian mature peptide is 19 amino acids — two residues longer than the salmon form — and retains the characteristic Cys-Cys disulfide-closed cyclic structure. The detailed neuroanatomy of the mammalian MCH system was mapped by Jackson Bittencourt, Paul Sawchenko, and colleagues, with the 1992 Journal of Comparative Neurology paper providing the canonical immunohistochemical and in-situ hybridization characterization of MCH-expressing neurons in the lateral hypothalamic area and zona incerta, with brain-wide axonal projections. The translational pivot from fish-pigmentation peptide to mammalian appetite signal came in 1996 with the Qu, Ludwig, Lowell, Maratos-Flier, and Flier Nature paper, which showed that MCH is upregulated in leptin-deficient ob/ob mice and that intracerebroventricular MCH administration stimulates food intake in rats. The genetic loss-of-function counterpart followed in 1998 with the Shimada, Tritos, Lowell, Flier, and Maratos-Flier Nature paper showing that MCH-knockout mice are lean and hypophagic. These two papers, both from the Flier and Maratos-Flier laboratories at Beth Israel Deaconess and Harvard, established MCH as one of the best-validated obesity targets in mammalian neuroendocrinology and launched the multi-decade pharmaceutical drug-discovery effort that has defined the field. Receptor pharmacology unfolded between 1999 and 2001. MCH-R1 (originally called SLC-1 or GPR24) was deorphanized in 1999 by Yumiko Saito, Olivier Nothacker, and Olivier Civelli at Takeda (Saito et al., Nature 1999) and concurrently by several other groups using reverse-pharmacology approaches. MCH-R2 was cloned in 2001 by multiple groups (including Hill et al. at GSK) and quickly recognized to be functional in primates and several non-rodent mammals but a non-functional pseudogene in rodents. The 2002 PNAS paper from Marsh, Weingarth, and colleagues at Merck reported the MCH-R1 knockout mouse, which is lean, hyperphagic with elevated metabolic rate, and resistant to diet-induced obesity — confirming MCH-R1 as the receptor responsible for MCH's orexigenic effects. The drug-discovery effort began in earnest in the early 2000s. SNAP-7941, the first widely used selective small-molecule MCH-R1 antagonist tool compound (Borowsky and colleagues at Synaptic Pharmaceutical, Nature Medicine 2002), produced anorectic activity in rodent obesity models alongside antidepressant- and anxiolytic-like effects, establishing MCH-R1 as a multi-domain CNS target. Over the following decade and a half, essentially every major obesity drug-discovery program — Amgen, Pfizer, GSK, AstraZeneca, Neurocrine, Procter & Gamble, Boehringer Ingelheim, Banyu/Merck, and others — pursued MCH-R1 antagonist series. Despite hundreds of compounds and multiple clinical candidates, no MCH-R1 antagonist has reached approval. The 2007 Mendez-Andino and Wos Drug Discovery Today review captured the field's frustration in its title — 'MCH-R1 antagonists: what is keeping most research programs away from the clinic?' — and identified cardiovascular (hERG-channel-related QT prolongation) and CNS tolerability (anxiety, mood, sleep) signals as the recurring failure modes. The MCH biology beyond feeding has continued to expand. REM sleep regulation was established by Laurent Verret and colleagues (BMC Neuroscience 2003), with MCH neurons firing selectively during paradoxical sleep. Reward and motivation roles in nucleus accumbens MCH-R1 signaling were developed across multiple laboratories. As of 2026, MCH-R1 antagonists for obesity remain a credible but unrealized translational story — the target validation is among the strongest in metabolic biology, but a tolerable approved medicine has not yet emerged.

How It Works

MCH was first found in fish, where it makes the skin pale by squeezing melanin pigment into tiny clumps inside skin cells — the opposite of what alpha-MSH does. In mammals, that fish-skin role barely exists. Instead, MCH is made by a specific group of neurons deep in the brain (the lateral hypothalamus) and acts as a powerful 'eat more' signal. Inject MCH into the brain of a rodent and it eats. Delete MCH or its receptor and the mouse stays lean even on a high-fat diet. That made MCH one of the most attractive targets for obesity drugs — and pharmaceutical companies spent decades trying to make pills that block its receptor. Despite excellent results in mice, no such drug has reached approval, mostly because the candidates ran into heart-rhythm or mood side effects.

MCH is encoded by the PMCH gene (preprohormone), which is processed to yield the mature 19-amino-acid cyclic peptide along with two additional fragments — neuropeptide-EI (NEI) and neuropeptide-GE (NGE) — whose physiological roles are less well characterized. The mature MCH peptide contains a conserved Cys7-Cys16 intramolecular disulfide that closes the molecule into a cyclic structure required for receptor binding. PMCH is expressed almost exclusively in neurons of the lateral hypothalamic area and zona incerta, with axonal projections throughout the brain — to the cortex, septum, amygdala, hippocampus, locus coeruleus, periaqueductal gray, dorsal raphe, ventral tegmental area, and other limbic and brainstem targets — making MCH a wide-projection peptide modulator analogous in anatomy to orexin/hypocretin (with which it partially co-localizes in adjacent lateral-hypothalamic neuronal populations). MCH signals through two GPCRs of the rhodopsin family. MCH-R1 (MCHR1, originally called SLC-1 or GPR24, deorphanized in 1999 by Saito and colleagues at Takeda and independently by several groups using reverse-pharmacology approaches) is the dominant receptor in all mammals. MCH-R1 couples primarily to Gi/o, inhibiting adenylate cyclase and lowering cAMP, with additional Gq/11 coupling in some cellular contexts that mobilizes intracellular calcium. MCH-R1 is widely expressed in the brain — densely in the nucleus accumbens, cortex, amygdala, and hippocampus, with significant expression in the hypothalamus and brainstem — providing the anatomical substrate for MCH's effects on feeding, reward, mood, and arousal. MCH-R2 (MCHR2), cloned in 2001 (Hill, Kafmann, and colleagues at GSK; Sailer, Sano, and colleagues at AstraZeneca; and several other groups concurrently), couples primarily to Gq/11 and is functionally expressed in primates (including humans), carnivores (dogs, ferrets), pigs, and several other lineages — but exists only as a non-functional pseudogene in rodents (mice, rats), a species difference that complicates translational pharmacology because rodent obesity models cannot test MCH-R2 contributions. Functionally, the dominant mammalian role of MCH is appetitive. Intracerebroventricular MCH administration in rats and mice rapidly and robustly stimulates food intake (Qu, Ludwig, Lowell, Maratos-Flier, Flier, Nature 1996), with the effect mediated primarily through MCH-R1 in feeding-relevant nuclei including the nucleus accumbens shell. MCH-knockout mice are lean, hypophagic, and resistant to diet-induced obesity despite intact leptin signaling (Shimada, Tritos, Lowell, Flier, Maratos-Flier, Nature 1998). MCH-R1-knockout mice are similarly lean, hyperphagic but with elevated metabolic rate and locomotor activity, and resistant to diet-induced obesity (Marsh, Weingarth, Novi, Schaeffer, and colleagues, PNAS 2002) — a phenotype consistent with MCH-R1 antagonist effects. MCH neurons in the lateral hypothalamus also fire selectively during REM sleep (Verret and colleagues, BMC Neuroscience 2003), implicating MCH in paradoxical-sleep regulation. Beyond feeding and sleep, MCH and MCH-R1 signaling modulate reward and motivation (with effects on cocaine, alcohol, and palatable-food self-administration), mood and anxiety (with antidepressant- and anxiolytic-like effects of MCH-R1 antagonists in rodent models — the SNAP-7941 paper by Borowsky and colleagues at Synaptic established the multi-domain pharmacology), and reproductive and developmental endocrinology.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Melanin-Concentrating Hormone:

• 01Whether a tolerable MCH-R1 antagonist for obesity will eventually emerge from medicinal chemistry — the target validation is among the strongest in metabolic biology, but cardiovascular and CNS tolerability liabilities have prevented every clinical candidate to date from reaching approval.
• 02The functional contribution of MCH-R2 in human and primate physiology — because rodents lack a functional MCH-R2, all rodent efficacy data reflect MCH-R1 pharmacology only, leaving open whether dual MCH-R1/R2 antagonism would be more effective or more tolerable than MCH-R1-selective antagonism in humans.
• 03Whether MCH-R1 antagonism would synergize with incretin-based obesity medications (GLP-1, GLP-1/GIP, GLP-1/glucagon, amylin) to produce additive or superior weight-loss efficacy — combination strategies have been proposed but not tested in adequately powered human trials.
• 04The role of MCH neurons in human REM sleep regulation and whether MCH-R1 modulation could be a therapeutic angle for narcolepsy, REM sleep behavior disorder, or sleep-disordered eating.
• 05The contribution of MCH signaling in the nucleus accumbens to human food-reward, palatability-driven eating, and binge-eating phenotypes — and whether MCH-R1 antagonism could be repositioned as an eating-disorder therapeutic rather than a general obesity drug.
• 06Whether the auxiliary peptides cleaved from the prepro-MCH precursor (NEI and NGE) have physiological roles independent of MCH itself, and whether they engage receptors beyond MCH-R1 and MCH-R2.
• 07The translational value of human PMCH, MCHR1, and MCHR2 polymorphism associations with obesity and eating-disorder phenotypes, and whether genetic stratification could identify subpopulations more likely to respond to MCH-R1 antagonist therapy.

Forms & Administration

MCH is not formulated or approved as a therapeutic in any jurisdiction. Research applications use synthetic mammalian MCH (the 19-amino-acid cyclic peptide) for in vitro receptor-binding and signaling assays, ex vivo tissue pharmacology, and intracerebroventricular or stereotactic intracranial administration in rodent feeding, sleep, and behavior models. Salmon MCH (the original 17-amino-acid form) is also commercially available as a reference peptide. Subtype-selective MCH-R1 agonists and antagonists, and a smaller set of MCH-R2 ligands, exist as research tools. Compounded MCH from peptide marketplaces has no validated clinical use.

Common Questions

Who Melanin-Concentrating Hormone Is NOT For

Drug & Supplement Interactions

There is no validated human drug-interaction profile for MCH because no MCH product has been clinically developed. Theoretical interactions follow from MCH's known signaling: at MCH-R1 receptors, MCH agonism modulates appetite and could in principle interact with other appetite-regulating agents (GLP-1 receptor agonists such as semaglutide and tirzepatide, melanocortin agonists such as setmelanotide, naltrexone-bupropion, and other anti-obesity medications). MCH signaling in mood and anxiety circuits suggests potential interaction with selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, and benzodiazepines. MCH-R1 antagonist drug-discovery candidates have repeatedly raised hERG-channel-related QT prolongation signals, suggesting that MCH-targeted ligands as a class warrant careful evaluation against other QT-prolonging medications (certain antiarrhythmics, antipsychotics, macrolide antibiotics, fluoroquinolones, methadone). None of these interactions has been characterized in controlled human studies; they are mechanistic possibilities that argue against casual exogenous MCH exposure rather than documented clinical events.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions